Lifeward Ltd. (NASDAQ: LFWD) announced a partnership with the Shirley Ryan AbilityLab to launch dedicated clinic days for its ReWalk Personal Exoskeleton, with the first sessions scheduled to begin in the second quarter of 2026.
Under the agreement, Lifeward will supply the ReWalk exoskeletons and provide technical support, while the AbilityLab will conduct clinical evaluations, training, and ongoing patient support at its Chicago campus. The arrangement is designed to streamline the evaluation and trial pathway, shortening the conversion cycle from lead to placement.
Lifeward’s financials underscore the strategic importance of the partnership. In Q1 2025 the company generated $5.0 million in revenue, down from $5.3 million in Q1 2024, and posted a net loss of $4.8 million. Revenue rose to $6.2 million in Q3 2025, and the company reaffirmed full‑year 2025 revenue guidance of $28 million to $30 million. The partnership aims to boost device placements and generate additional revenue streams while providing data that can strengthen future reimbursement arguments.
The collaboration leverages the AbilityLab’s reputation as the nation’s #1 spinal‑cord injury rehabilitation hospital, offering Lifeward access to a large, qualified patient population and a clinically validated environment. The partnership is expected to enhance real‑world outcome data collection, supporting Lifeward’s ongoing efforts to expand Medicare and commercial payer coverage.
Mark Grant, Lifeward’s CEO, said the partnership is a first for the company and will “streamline the pathway from evaluation to real‑world use of the ReWalk Personal Exoskeleton.” The move is positioned as a strategic step to accelerate adoption, improve revenue, and strengthen the company’s cash position.
The partnership represents a significant operational milestone that could materially influence Lifeward’s future revenue trajectory, but its ultimate impact will depend on successful execution and continued reimbursement expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.